Clinical Trials Logo

Fatigue Syndrome, Chronic clinical trials

View clinical trials related to Fatigue Syndrome, Chronic.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06257420 Enrolling by invitation - Clinical trials for Myalgic Encephalomyelitis

Rapamycin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

ME/CFS
Start date: December 11, 2023
Phase:
Study type: Observational

The goal of this observational study is to assess the clinical response and the effect of autophagy function in ME/CFS patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are: - Does rapamycin reduce the overall symptom burden of ME/CFS and does it improve the quality of life? - Does rapamycin change mTOR driven autophagy deficits observed in a subset of ME/CFS patients? Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy.

NCT ID: NCT05866952 Enrolling by invitation - Dyspnea Clinical Trials

Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection

PASC VQ
Start date: June 5, 2023
Phase:
Study type: Observational

Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations

NCT ID: NCT05273372 Enrolling by invitation - Fatigue Clinical Trials

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

There is no approved treatment for fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a condition with as many as 2.5 million people in the US. Initial case studies have shown an improvement in fatigue in ME/CFS with anhydrous enol-oxaloacetate (AEO). This randomized, double blinded, placebo controlled trial will seek to further evaluate the efficacy of AEO to reduce fatigue in ME/CFS, based on change in the Chalder Fatigue Score (Likert Scoring) of the AEO group against the placebo group at 90 days. As secondary evaluations on other core ME/CFS symptoms, the investigators are measuring the health related quality of life as assessed by the SF-36, hours of upright activity, functional capacity (activity, steps, cognition, and heart rate variability), and general health status (global change, vitals) Finally, this test will gain preliminary insights on the safety, tolerability, and efficacy of AEO in ME/CFS patients.

NCT ID: NCT03409653 Enrolling by invitation - Fibromyalgia Clinical Trials

Complex Chronic Diseases Program Data Registry

Start date: June 12, 2017
Phase:
Study type: Observational [Patient Registry]

The purpose of this data registry is to prospectively collect data from patients referred to an Complex Chronic Diseases Program (CCDP) at BC Women's Hospital + Health Centre to assess the quality of life of the CCDP Patients before, during and after their care at the CCDP.

NCT ID: NCT03254823 Enrolling by invitation - Clinical trials for Chronic Fatigue Syndrome

Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Start date: March 28, 2018
Phase:
Study type: Observational

This study investigates whether there is an immune response directed against gut microbes or food and parts of the body in severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients.